This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cubist Unveils Five-Year Strategic Goals

Stocks in this article: CBST

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the Company’s five-year strategic aspirations – Building Blocks of Growth – at its Investor Day at the NASDAQ Market Site. Cubist’s President and Chief Executive Officer Michael Bonney shared the Company’s five-year roadmap, including goals for top- and bottom-line growth, future pipeline developments, and cultural elements that will position Cubist to deliver long-term, sustainable growth.

As detailed at the Company’s Investor Day, by year-end 2017 Cubist expects to:

  • Grow global revenue to $2 billion annually;
  • Have four product candidates in late-stage clinical trials;
  • Generate $700 million in non-GAAP annual adjusted operating income; and
  • Continue to strengthen and develop the Company’s highly differentiated culture.

“Through our transformation over the past two years, Cubist has established itself as a global leader in the acute care/hospital environment. Our Building Blocks of Growth will help us build on this momentum as we look to deliver important new medicines for patients and drive long-term value for our customers and shareholders,” said Mr. Bonney. “The next five years represent an extraordinary time of opportunity for Cubist, and our entire team is excited to deliver on the Company’s very promising future.”

Grow Global Revenue to $2 Billion

Cubist plans to generate $2 billion in global annual revenue in 2017, driven largely by organic growth.

To achieve this goal, the Company expects to:

  • Drive CUBICIN® (daptomycin for injection) growth across the U.S. and around the world through its global partnerships. By year-end 2017, the Company expects CUBICIN will well-exceed $1 billion in U.S. sales alone;
  • Expand the growth of ENTEREG® (alvimopan), which is expected to approach $100 million in sales by year-end 2017;
  • Optimize its current late-stage pipeline, led by CXA-201, CB-315, and CB-5945;
  • Build out its global commercial footprint in a targeted manner; and
  • Pursue in-licensing, partnership, and/or M&A activity as part of its active, focused, and disciplined business development program.

Four New Product Candidates in Late-Stage Clinical Trials

Cubist expects to have four new product candidates in late-stage clinical trials by year-end 2017. The Company will build on its successful balance between strong internal discovery efforts and active business development, focused on potential therapies for patients in the acute care/hospital environment.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs